Nexobrid (Concentrate Of Proteolytic Enzymes Enriched In Bromelain)

Concentrate of proteolytic enzymes enriched in bromelain, the active ingredient in Nexobrid, is a proteolytic enzyme presented as a topical gel for cutaneous use. It enzymatically debrides deep partial‑thickness burn wounds, selectively removing necrotic tissue to support healing in patients with severe burns.

GNH USA supplies Nexobrid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nexobrid is a proteolytic enzyme indicated for the management of burn injuries where selective debridement is required. - Deep partial‑thickness burns: enzymatic removal of necrotic tissue to facilitate wound healing. - Mixed depth burns: selective debridement of non‑viable tissue while preserving viable dermis. - Burn wound preparation for grafting: clears devitalized tissue to improve graft take and outcomes.

Nexobrid may cause local and systemic adverse reactions following topical application.

Common Side Effects: - Local pain at the application site. - Redness or erythema of surrounding skin. - Swelling or edema around the treated area. - Mild bleeding or oozing from the debrided wound. - Itching or mild irritation.

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis. - Deep tissue necrosis extending beyond target area. - Secondary infection of the wound. - Systemic hypersensitivity symptoms such as fever or malaise. - Persistent severe pain requiring medical intervention.

When using Nexobrid, clinicians should follow specific safety measures to minimize risks. - Assess burn depth: confirm that the wound is appropriate for enzymatic debridement. - Avoid application on healthy, uninjured skin. - Monitor for signs of allergic reaction during and after treatment. - Do not use in patients with known bromelain or pineapple allergy. - Ensure proper wound cleaning and aseptic technique prior to application. - Store below 25°C: keep in original container, protect from moisture and light.

Nexobrid may interact with other agents applied to the wound or systemic medications affecting hemostasis.

Major Interactions (Avoid): - Concurrent systemic anticoagulants: increased risk of bleeding at the treatment site. - Use with other topical debriding agents: additive tissue damage.

Moderate Interactions (Monitor Closely): - Topical antibiotics: may alter wound flora and affect healing. - Local NSAID preparations: potential for increased irritation. - Systemic protease inhibitors: may reduce enzymatic activity of Nexobrid.